Key statistics
As of last trade Ocugen Inc (2H51:MUN) traded at 1.41, -14.77% below its 52-week high of 1.66, set on Jan 15, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.54 |
|---|---|
| High | 1.54 |
| Low | 1.41 |
| Bid | 1.45 |
| Offer | 1.50 |
| Previous close | 1.54 |
| Average volume | 45.28k |
|---|---|
| Shares outstanding | 327.89m |
| Free float | 319.88m |
| P/E (TTM) | -- |
| Market cap | 596.76m USD |
| EPS (TTM) | -0.2167 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 08:25 GMT.
More ▼
Announcements
- Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
- Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
- Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
- Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
- Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
- Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
- Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
- Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
- Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
More ▼
